Dexamethasone Implant in Patients with Diabetic Macular Edema Resistant to Anti-VEGF Therapy
Küçük Resim Yok
Tarih
2019
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Turkish Ophthalmological Soc
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Objectives: To investigate the efficacy of single dose intravitreal dexamethasone implant in patients with diabetic macular edema (DME) resistant to anti-VEGF therapy. Materials and Methods: Twenty eyes of 14 patients (8 male, 6 female; mean age, 65 +/- 5.7 years) with DME resistant to intravitreal ranibizumab injections were studied. A single intravitreal dexamethasone implant was injected into each eye and patients were followed up for 6 months. Response to therapy was assessed monthly by measuring intraocular pressure (IOP), best-corrected visual acuity (BCVA), and central foveal thickness (CFT). Results: Baseline (before injection) IOP was 14.9 +/- 2.7 mmHg and did not change significantly in the six months following injection. Baseline BCVA was 1.04 +/- 0.35 LogMAR and improved to 0.86 +/- 0.31 at month 1 without statistical significance (p=0.056). CFT was significantly lower in all monthly measurements compared to its baseline value of 682.21,229.2 mu m. During the follow-up period, endophthalmitis, significant cataract, or rhegmatogenous retinal detachment were not detected. Conclusion: Intravitreal dexamethasone implant injection is associated with significant CFT reduction for up to six months without causing any complications. Although BCVA did not improve in parallel with the CFT reduction, intravitreal dexamethasone implant should be considered as an effective and safe treatment option in the management of DME patients resistant to anti-VEGF injections.
Açıklama
Anahtar Kelimeler
Dexamethasone, diabetic macular edema, ranibizumab, vascular endothelial growth factor
Kaynak
Turk Oftalmoloji Dergisi-Turkish Journal of Ophthalmology
WoS Q Değeri
N/A
Scopus Q Değeri
Cilt
49
Sayı
2
